XML 49 R35.htm IDEA: XBRL DOCUMENT

ACQUISITIONS (Tables)

12 Months Ended

Oct. 31, 2020

Schedule of the fair value of assets and liabilities assumed

The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of August 23, 2019 (in millions):


Cash and cash equivalents			$	10
Accounts receivable			28
Inventories			21
Other current assets			2
Property, plant and equipment			8
Intangible assets			641
Goodwill			483
Total assets acquired	$	1,193
Accounts payable			(4)
Deferred revenue			(5)
Employee compensation and benefits			(7)
Other accrued liabilities			(2)
Long-term debt			(4)
Net assets acquired			$	1,171

Components of intangible assets acquired

The components of intangible assets acquired in connection with the BioTek acquisition were as follows (in millions):


	Fair Value			Estimated Useful Life
Developed product technology		$	387	5-13 years
Customer relationships		202		3-8 years
Backlog		5		2 months
Tradenames and trademarks		43		10 years
Total intangible assets subject to amortization		$	637
In-process research and development		4
Total intangible assets		$	641

Proforma operating results

The following represents the unaudited proforma operating results as if BioTek and ACEA had been included in the company's consolidated statements of operations as of the beginning of fiscal 2018 (in millions, except per share amounts):


	2019		2018
Net revenue	$	5,308	$	5,112
Net income	$	1,012	$	210
Net income per share — basic	$	3.22	$	0.65
Net income per share — diluted	$	3.18	$	0.65